De Novo Inflammatory Bowel Disease After Bariatric Surgery a Case Series and Literature Review
Click hither for correspondence accost and email
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN, USA
| Date of Submission | 21-January-2021 |
| Appointment of Acceptance | 25-Mar-2021 |
| Date of Spider web Publication | 24-Aug-2021 |
 Abstract |
In dissimilarity to previous perceptions that inflammatory bowel disease (IBD) patients are mostly malnourished and underweight, there is mounting show to propose that rates of obesity in IBD now mirror that of the general population. IBD is an allowed-mediated status that appears to develop in individuals who have not merely a genetic predisposition to immune dysregulation but besides likely exposure to various environmental factors which further potentiate this risk. With the surge in obesity alongside the rising incidence of IBD, particularly in developing nations, the part that obesity may play, not only in the pathogenesis just likewise in the natural history of disease has become a topic of growing interest. Currently available data exploring obesity'due south impact on the natural history of IBD are largely conflicting, potentially limited by the use of body mass index as a surrogate measure out of obesity at varying fourth dimension points throughout the disease grade. While there are pharmacokinetic data to suggest possible detrimental effects that obesity may have on the response to medical therapy, results in this realm are besides inconsistent. Moreover, not simply is it unclear whether weight loss improves IBD outcomes, little is known about the condom and efficacy of available weight-loss strategies in this population. For these reasons, it becomes increasingly important to further understand the nature of any interaction betwixt obesity and IBD.
Keywords: Crohn's illness, inflammatory bowel disease, obesity, ulcerative colitis
How to cite this commodity:
Johnson AM, Loftus EV. Obesity in inflammatory bowel affliction: A review of its role in the pathogenesis, natural history, and treatment of IBD. Saudi J Gastroenterol 2021;27:183-ninety
How to cite this URL:
Johnson AM, Loftus EV. Obesity in inflammatory bowel disease: A review of its part in the pathogenesis, natural history, and treatment of IBD. Saudi J Gastroenterol [serial online] 2022 [cited 2022 Apr 19];27:183-xc. Bachelor from: https://www.saudijgastro.com/text.asp?2021/27/four/183/319164
Obesity is on the ascension in the IBD population with many estimates now citing that betwixt xv% and 40% of these patients are obese.[1],[2],[iii],[four],[5] Not only exercise these findings change our prior conceptions about IBD patients being plagued by low body weight, but they spark numerous curiosities regarding the potential involvement of obesity in the pathogenesis of IBD, its touch on the natural history of illness, and how it may affect medical and surgical management for these patients.
It is increasingly recognized that obesity itself represents a low-form inflammatory state and has been implicated every bit a run a risk factor for adverse outcomes in a number of other chronic inflammatory atmospheric condition.[6] While historically it had been thought that adipose tissue was but an inert fat repository, it is now more widely appreciated that it serves as an active endocrine organ producing a large cytokine milieu, termed adipokines, some of which are proinflammatory (such as tumor necrosis factor [TNF] α or interleukin [IL]-vi) and others anti-inflammatory (adiponectin) in nature.[7] Additionally, the varying forms of adiposity each take unique biochemical profiles. For instance, the creeping fatty associated with Crohn'south disease (CD) yields a different cytokine milieu equally compared to visceral or subcutaneous (SC) fatty stores.[eight],[ix] Every bit a effect, it has been hypothesized that overexpression of diverse adipokines in the visceral fatty of obese IBD patients may potentiate the inflammatory cascade in IBD.
The incidence of IBD appears to exist on the ascension, peculiarly in developing nations where it was previously uncommon.[10] A major commonality amidst the geographic regions seeing a spike in the incidence of IBD is that of increasing westernization, a lifestyle shift which includes many environmental triggers hypothesized to contribute to the risk of de-novo IBD. This includes dietary changes, alterations in the microbiome, improved hygiene, and increased antibody employ.[eleven] Dietary changes characteristic of modernized societies often includes heavier reliance on processed foods, an animal-sourced equally opposed to establish-based diet, increased consumption of simple sugars and carbohydrates, and overall increased calorie consumption. While at that place are data to suggest that dietary factors may represent an environmental trigger in the pathogenesis of IBD,[12] we must also consider that the same dietary changes arguably result in a social club with higher rates of obesity. It is well established that obesity has get a major global health effect in recent decades, and with this increased prevalence alongside the rising incidence of IBD in developing nations, obesity should also be considered as a take a chance factor in the pathogenesis of IBD.[thirteen]
Studies attempting to review the true clinical impact that premorbid obesity has on the development of de-novo IBD are conflicting. One big cohort report suggested that obesity in early adolescence was associated with an increased take chances of CD, with onset prior to the historic period of 30 years, merely inversely associated with the gamble of future UC diagnosis at any age.[14] Conflicting data from the European Prospective Investigation into Cancer and Nutrition cohort establish no such clan between body mass index (BMI) and future risk of ulcerative colitis (UC) or CD.[15]
Given the data to support the detrimental event that obesity may have on other immune-mediated conditions such as psoriasis and rheumatoid arthritis (RA),[vi],[xvi] it stands to reason that this relationship would be explored in patients with IBD. While there are a few studies which take attempted to answer these questions, results have been inconsistent.
Ulcerative colitis
Very few studies have explored the part that obesity plays in UC-related outcomes. A retrospective analysis of 267 UC patients in Olmsted County, Minnesota, assessed the association between BMI at the time of IBD diagnosis and subsequent IBD-related complications and found that with each incremental increment in BMI by one kg/m2, the risk of hospitalization and surgery rose by 3.iv% and five%, respectively.[17] In contrast to this, some other retrospective review of 284 UC patients suggested that those who were overweight and obese had a lower hazard of complications every bit a composite endpoint including anti-TNF apply, colectomy, or hospitalization.[two] Finally, yet another review reported no difference in rates of corticosteroid use, hospitalization, surgery, or emergency department visits in obese versus normal-weight IBD patients.[ane]
Crohn'due south affliction
While at that place are more than studies assessing the impact of obesity on CD outcomes, data are similarly thin and inconclusive. Many of the studies reviewing the bear on of obesity on CD outcomes seem to suggest that obesity may actually accept a protective effect. A retrospective review of 221 CD patients from Olmsted Canton, Minnesota, demonstrated that the hazard of future surgery decreased past v% for each incremental increase in BMI by 1 kg/grand2 at the time of their CD diagnosis, while at that place was no departure in risk of future hospitalization or corticosteroid employ.[17] Some other retrospective report demonstrated that obese CD patients had lower rates of corticosteroid employ, anti-TNF therapy, hospitalizations, and surgeries equally compared to their normal-weight counterparts.[2] Lower rates of penetrating illness behavior have also been documented in obese CD patients.[three] On the other hand, others have reported no difference in rates of complications stratified by BMI.[1],[4]
Medical management
With the increasing prevalence of obesity inside the IBD population, it becomes prudent to empathise the impact that information technology may have on medical therapy. Several studies have suggested that obesity may be a negative prognostic factor in a patient's response to medical therapy, with multiple postulated mechanisms. As previously noted, obesity is thought of as a chronic inflammatory state, based on the thought that information technology potentiates a chronic low-grade activation of the allowed system resulting in increased levels of circulating cytokines, including TNF-α.[vii] Additionally, it has been demonstrated that obesity may affect pharmacokinetics of drugs past increasing the volume of distribution and drug clearance, thereby resulting in shorter half-life and lower trough drug concentrations.[xviii],[xix] Finally, there is besides a hypothesized miracle known as a "TNF sink," whereby monoclonal antibody clearance is more rapid due to unbound antigen targets "sopping upward" antibody-"which may be more pronounced with the higher inflammatory burden in obese patients.[twenty]
Antitumor necrosis factor α therapy
There are data to suggest that obesity may be a predictor of suboptimal response to anti-TNF-α agents.[21] Multiple mechanisms for this suboptimal response have been implicated. Starting time of all, obesity has been demonstrated in pharmacokinetic studies to event in lower drug trough levels, likely related to increased book of distribution and drug clearance.[xviii],[19] A previous study of adalimumab in psoriasis patients revealed that trunk weight was the biggest predictor of drug clearance and volume of distribution.[22] Similar findings were also documented for certolizumab pegol use in CD patients, noting that increased torso surface surface area resulted in increased drug clearance and book of distribution.[23] The same has also been noted with apply of intravenous (IV) anti-TNF, infliximab, in a variety of immune-mediated atmospheric condition.[24],[25] The accelerated clearance and higher volumes of distribution in obesity appear to exist associated with lower trough levels, resulting in either reduced response or increased loss of response to anti-TNF agents.
Some take theorized that these variations may lie in the altered pharmacokinetics of SC versus 4-based therapies.[26] In a retrospective review of CD patients treated with adalimumab or infliximab, obese patients on adalimumab experienced shorter time to loss of response and increased requirement for dose escalation, although the same was not true for those on infliximab.[27] In addition to the differing commitment mechanisms between adalimumab and infliximab, it has also been suggested that the fixed dosing of adalimumab, as opposed to the weight-based dosing scheme of infliximab, could reduce the likelihood that obese patients receive weight-appropriate therapy. However, a retrospective review of 1494 IBD patients demonstrated that as BMI increased, there was a significant decrease in the commitment of weight-appropriate dosing, and this was true for both IV and SC dosing.[1] Findings such equally these have further supported the idea that there may be something intrinsic to obesity resulting in reduced handling response, independent of drug levels.
There are multiple studies suggesting that obese patients may be at higher take a chance of anti-TNF failure regardless of the fashion of assistants and whether they are weight based or fixed dose.[28],[29] However, there are data to contradict that idea, including a pooled analysis of data nerveless from the Accent-I, ACT-one, Act-ii, and SONIC trials of infliximab, suggesting that BMI had no bear on on rates of clinical remission.[thirty] A contempo meta-analysis by Singh and colleagues suggested that obesity was associated with a sixty% higher odds of nonresponse to anti-TNF therapy across multiple allowed-mediated weather (OR, 1.60; 95% CI, i.39–ane.83), with each 1 kg/kii increase in BMI producing a vi.5% higher odds of declining anti-TNF therapy (OR, one.065 [1.043–1.087], I 2 = 5%).[31] This risk remained when comparing those treated with either weight-based or fixed-dose regimens. However, when IBD was evaluated independently (i.e., without inclusion of other immune-mediated conditions such as RA and psoriatic arthritis), obesity did non seem to have the same bear upon on loss of response.
Ustekinumab
Ustekinumab is the first and currently only clinically available inhibitor of IL-12 and 23, exerting its effect by binding the p40 subunit and interfering ultimately with production of the Th1-and Th17-dependent proinflammatory cytokines. As this drug is a more contempo addition to the therapeutic armamentarium in IBD, there are far less data in regards to the impact obesity may accept on treatment response. A mail service-hoc assay of the IM-UNITI trial, which assessed ustekinumab for maintenance of CD, reviewed whether BMI had whatsoever influence of accomplishment of clinical or corticosteroid-free remission.[32] The investigators constitute that although ustekinumab trough levels were significantly lower in obese patients (median 2.98 mcg/mL) as compared to those who were considered overweight (4.84 mcg/mL; P = 0.021) or underweight/normal weight (4.43 mcg/mL; P = 0.014)-"there were no differences in the rates of clinical remission.
Vedolizumab
Vedolizumab exerts its effect by inhibiting the blastoff-4-beta-7 integrin receptor, resulting in its gut-selective anti-inflammatory machinery of action. Similar to ustekinumab, at that place are sparse information regarding how obesity may touch on vedolizumab'due south effectiveness in the treatment of IBD. Data are express to a study of 83 patients including those with antibiotic-dependent or refractory pouchitis and CD of the pouch, in whom BMI was not predictive of clinical response.[33]
Immunomodulators
Both azathioprine (AZA) and vi-mercaptopurine are dosed according to weight. Consequently, obesity has been suspected to be a detrimental risk factor for suboptimal weight-based dosing and therapeutic response, equally we know that acceptable levels of the thiopurine metabolite, 6-thioguanine (6-TGN), accept been associated with improved outcomes in IBD.[34]
A retrospective review of 1176 IBD patients reviewed the impact of obesity on the effectiveness of immunomodulators, based on frequency of illness flares, defined as the initiation of or increase in corticosteroid use. The authors reported that UC patients with a BMI >25 kg/yard2 had reduced response to AZA as compared to those with a BMI <25 kg/thousandii, while there were no differences noted in patients with CD. Nonetheless, they noted that in CD patients who discontinued their AZA, those with BMI >25 were less likely to flare as compared to their normal-weight counterparts.[35]
Some other retrospective analysis of an IBD cohort found that vi-TGN levels were reduced past 8% with each 5 kg/thou2 increase in BMI.[36] The natural assumption may be that obese patients merely were unable to achieve adequate weight-based therapy, but what was interesting is that these obese patients were more than likely to have sub-therapeutic vi-TGN levels even when adjusting for the total dose of thiopurine relative to torso weight, in that the average dose per kilogram of thiopurine was like in the sub-therapeutic (1.70 mg/kg), therapeutic (1.63 mg/kg), and supra-therapeutic (1.81 mg/kg) groups (P = 0.879). Additionally, they noted that patients with BMI >30 seemed to accept a skewed metabolism toward higher methylmercaptopurine nucleotide (MMPN) levels resulting in a higher MMPN: TGN ratio >eleven, which could not be accounted for by variations in thiopurine methyltransferase activity or dose per kilogram of body weight.[36] These differences were hypothesized to exist secondary to either contradistinct pharmacokinetics in obese individuals or potential alterations in thiopurine metabolism related to increased expression of a genetic transregulator known equally Kruppel-like factor (KLF14) in adipose tissue.
Corticosteroids
Corticosteroids are a mainstay in the management of astute IBD flares. While they are quite efficacious in the short term for induction of remission, prolonged use is not recommended and often results in significant adverse effects. One of the more than usually reported side effects is that of weight gain, reported subjectively in approximately 70% of patients on chronic corticosteroids.[37]
A systematic review on the influence of glucocorticoids across a multifariousness of inflammatory atmospheric condition concluded that evidence was lacking to suggest major alterations in energy intake and trunk weight or composition with short-term (<12 weeks) employ of glucocorticoids; yet, long-term (>12 weeks) use could impart clinically significant changes in body weight.[38] However, in that location was significant heterogeneity within this written report regarding the affliction indications and dosing regimen for corticosteroids, too equally the duration of use and chief consequence used to measure body composition. Whether obesity impacts the efficacy of corticosteroid employ, or if weight gain associated with long-term corticosteroid use negatively influences IBD outcomes, is unclear.
Despite the expansion of our armamentarium of IBD therapies over the years, a proportion of patients will ultimately require surgical management of their disease. It has been well documented that obesity may impart an increased adventure of short-term perioperative complications in patients undergoing abdominal operations, namely, surgical site infections or wound complications.[39] Obesity besides appears to increase intraoperative times, overall complication of intra-intestinal operations, and the likelihood of conversion from laparoscopic to open procedures.[40] Technical challenges that obesity may generate with respect to usually performed IBD-related operations of stoma formation and ileal pouch-anal anastomosis (IPAA) are worth special mention.
The germination of a stoma is commonplace in the surgical direction of IBD, including either ileostomy or colostomy with the intent of temporary diversion, as well equally those destined for more permanent use. Identifying an ideal location for stoma placement is paramount, a task which may pose added challenges in an obese patient due to a number of issues including altered intestinal contour, increased abdominal wall thickness, or large pannus. This tin be farther complicated when a stoma is necessary for an emergent indication and the typical preoperative planning is non possible or made more hard due to the patient'southward tenuous clinical condition or abdominal distention. In addition to confirming the technical feasibility of ostomy germination, it must be assured that the patient is able to readily access and visualize their stoma site, meaning that often for obese patients, a site above the omphalos may be more realistic. Even with the best of attempts at identifying and creating a stoma in an ideal location, studies have demonstrated that probable as a outcome of increased abdominal adiposity, excessive stomal tension, and same technical challenges, obese patients remain at college risk of stoma-related complications such as parastomal hernia, stomal prolapse or retraction, and mucocutaneous separation.[41],[42]
In a subset of patients for whom an ileostomy is temporary, the intended destination for many is an IPAA, which tin can be significantly more challenging in the setting of obesity for a myriad of reasons. Often the mesentery of obese patients is increasingly fatty and ultimately foreshortened, making it sometimes difficult if not impossible to achieve the adequate length of bowel to extend to the pelvic floor for pouch construction. Obesity besides creates challenges for the pelvic exposure necessary to perform restorative proctocolectomy with IPAA. While there are reports suggesting that these issues may increase the risk of postoperative complications such as pelvic sepsis, which can exist an important predictor of long-term pouch role,[42] others take suggested that for obese patients who undergo 3-stage IPAA with use of a diverting stoma in high-volume centers, long-term outcomes may be like.[40] The potential added advantage of pursuing IPAA in 3 stages is that this may provide a window of opportunity post-obit abdominal colectomy and ileostomy formation for the patient to pursue intensive weight-loss strategies prior to restoration of bowel continuity.
With how pervasive obesity has get inside the IBD population, information technology has become increasingly important to understand what, if whatever, touch weight loss may have on IBD-specific outcomes. While information technology is well appreciated that weight loss favorably impacts outcomes in a multitude of chronic diseases, including other immune-mediated conditions similar psoriasis,[43] the issue it may accept on the natural history of IBD is largely unknown. A prospective trial assessing the bear upon of weight reduction on therapeutic response to TNF inhibitors in the psoriasis population found that patients who were randomized to low-calorie diet and lost an boilerplate of 12.9 kg had significantly higher rates of clinical improvement every bit compared to patients who were offered no dietary intervention and did non lose weight (85.9% vs. 59.3%, P < 0.001).[44] Results such as this generate further involvement in exploring the impact weight loss may have in the IBD population.
Gimmicky strategies for weight loss include lifestyle modifications, medications, bariatric surgery, and more than recently bariatric endoscopy. The initial strategy recommended for weight loss in the full general population is a comprehensive lifestyle intervention encompassing a combination of nutrition, concrete activeness, and behavioral modifications. Certainly, this approach should too be considered first-line in IBD patients, although it is likely advisable to take patients pursue such interventions under the direction of a certified dietician, every bit there may be some special challenges inherent to this population that needs to be considered. Depending on the degree of intestinal inflammatory burden, it may not exist feasible for patients with active affliction to tolerate many "healthy" foods such every bit fruits and vegetables that are often function of a diet strategy. Moreover, this is a population who may be prone to a variety of vitamin and micronutrient deficiencies despite being overweight, so special attention should be paid to ensuring a well-balanced diet plan. Physical activity has documented favorable impact on not just physical but also psychological well-being in otherwise good for you individuals. There has been some interest in the potential positive effect practise may have in modulating IBD activity, which may accept some biologic rationale. Moderate-intensity do may impart an anti-inflammatory result through a number of mechanisms, including the reduction of visceral fat and thereby reduced secretion of proinflammatory adipokines, too as past diminishing stress-induced abdominal barrier dysfunction.[45] Several retrospective or survey-based clinical studies accept found that IBD patients who exercise have improved sense of well-beingness and quality of life.[46],[47] An additional prospective written report utilizing the Crohn's and Colitis Foundation of America Partners cyberspace-based cohort suggested that the risk of active illness in CD and UC patients was reduced in those with higher levels of practice.[48] Information technology is of import to annotation, however, that these studies all focused on subjective measures of well-being, without any specific objective markers of illness action.
While in that location are a handful of prescription medications bachelor for weight loss, none have been studied in the IBD population. Similarly, with most endoscopic bariatric interventions beingness recent developments in the sphere of weight loss, there are no data on their use in IBD patients. A item endoscopic modality worth mentioning includes intra-gastric balloon therapy, whereby a soft saline-filled balloon is inflated in the stomach to promote early on satiation as well as perhaps delayed gastric emptying, resulting in a restrictive-based weight-loss strategy. The temporary, reversible, and minimally invasive nature of this intervention could exist an intriguing option in a subset of IBD patients. One may envision its potential for apply in patients who require weight loss prior to pursing IPAA formation post-obit the first stage of restorative total proctocolectomy. All the same, there are no formal studies reviewing the apply of such balloons in CD or UC patients, and currently IBD is considered a contraindication for their apply-"further restricting options in this population.
For the general population, obese patients who accept not achieved acceptable weight reduction with the above interventions and who accept a BMI either ≥40 kg/mtwo or between 35 and 39.nine kg/mtwo with at least i obesity-related comorbid condition, bariatric surgery has been shown to be superior to diet and lifestyle interventions and also reduce mortality.[49] While IBD has classically been considered a relative contraindication to bariatric surgery, given the ascension rates of obesity inside this population, a few recent studies take attempted exploring the condom and feasibility of bariatric surgery in these patients. A cohort study of 719 IBD patients identified from the National Inpatient Sample found that while IBD patients had a higher risk of peri-operative minor bowel obstacle equally compared to non-IBD patients (adjusted odds ratio, four.0; 95% CI, 2.2–74), the mortality hazard and rates of other major postoperative complications were low-"suggesting information technology is probable safe and viable at least in the short term.[50] An additional smaller retrospective series reviewing 20 IBD patients demonstrated that not only was the functioning of bariatric surgery prophylactic, feasible, and an effective weight-loss strategy-"but that it may take resulted in improved IBD outcomes. This was based on the finding that ix of 10 patients on IBD pharmacotherapy reported significant improvement in their IBD symptoms postoperatively in follow-up.[51] Further supporting this idea was a case-control study including 25 IBD patients who underwent bariatric surgery, matched to IBD patients without bariatric surgery. During a median follow-upward of over 7 years, they institute that corticosteroid apply and IBD-related surgery were less common in those who had bariatric surgery as compared to controls.[52]
There have likewise been a few case serial describing the onset of de-novo IBD post-obit bariatric surgery. For case, Braga et al. [53] described new onset IBD in 44 patients who had previously undergone bariatric surgery, most commonly Roux-en-Y gastric bypass, after a median latency period of 7 years. With the very small numbers of reported cases, whether this is truly a causal relationship is unclear. Theorized mechanisms behind this potential association include the function of excess toxin exposure to the intestinal tract every bit a event of the altered beefcake, increased release of proinflammatory adipokines from shifts in adipose tissue, or alterations in the microbiome.[53],[54]
Limitations and future directions
At this time, our understanding of the true impact that obesity has on the pathogenesis, natural history, and treatment of IBD is constrained by insufficient and contradictory data. A major limitation of the existing literature regarding the interaction of obesity and IBD is the dependence on BMI as a measure of obesity. As previously noted, the distribution of adipose tissue is separated into various compartments, which each encompass their own biochemical profile, and is likely more clinically meaningful than BMI. BMI unfortunately is a crude measurement tool for accurately assessing adiposity, as information technology does not differentiate lean trunk mass from other tissue forms. Utilizing volumetric analysis of visceral fat via cantankerous-exclusive imaging studies would likely be the preferred means of assessing adiposity over BMI and may correlate more than with IBD-related outcomes. As part of the randomized postoperative Crohn's endoscopic recurrence trial, investigators found that visceral adipose tissue, every bit measured on cross-sectional abdominal imaging, was an independent run a risk cistron for endoscopic recurrence of CD following surgical resection of all macroscopic disease (relative risk, 2.i; 95% CI, ane.5–iii.0; P = 0.012).[55] Another retrospective review found that in 143 CD patients who underwent ileocolectomy, the visceral-to-SC fat ratio was an independent predictor of postoperative morbidity, whereas BMI was not.[56]
In improver to the use of BMI as a surrogate measure of obesity, at that place is wide variation betwixt available studies in the timing that BMI is measured. This is of import, given it is not clear at what time point obesity may impart any impact it has on the natural history of IBD. For case, is this established already in babyhood years before disease onset, is the weight at the time of diagnosis of import, or is obesity a fluid influence changing throughout the course of disease? Nigh available studies capture BMI at variable time points throughout the disease process, which besides leaves these measurements susceptible to misreckoning factors such as corticosteroid exposure, tobacco use, or disease activity which may affect an individual'south weight.
To further our understanding of the true influence obesity may have on the affliction course of IBD, we would benefit from prospective studies utilizing measurements of visceral adipose tissue as a mark of obesity rather than BMI, as well as better adjustment for confounding factors such every bit smoking, corticosteroid use, and affliction severity.
The prevalence of obesity within the IBD population has risen considerably over fourth dimension and at present parallels that of the general population. While there are biologically plausible mechanisms to support a connection between obesity and IBD, epidemiological data are conflicting on any role obesity may play in the pathogenesis or natural history of the disease. Inherent limitations in study blueprint, including the use of BMI as a surrogate measure, may contribute to some of the discrepancy, as visceral adiposity is more likely to be liable in promoting the inflammatory cascade and does not correlate well with BMI.
Information technology is logical to surmise that obesity may impact the response to medical therapy past altering the pharmacokinetics of drug assimilation, metabolism, and clearance-"resulting in suboptimal drug levels which we know to be predictors of response. All the same, there are also data to suggest that obesity may negatively influence response to therapy independent of therapeutic drug levels, possibly related to a higher circulating burden of proinflammatory adipokines such every bit TNF-α due to increased visceral adiposity. With this in heed, some have argued that obese IBD patients may benefit from the use of weight-based medications such as infliximab along with more aggressive monitoring of drug levels throughout the grade of their affliction.
With the now pervasiveness of obesity within the IBD population, coupled with its potential negative prognostic implications, weight loss would seem to exist an obvious goal as function of the management image. Yet, we have very limited data to know whether weight loss positively impacts IBD outcomes. Moreover, many weight-loss strategies bachelor to the full general population have classically been relatively contraindicated or not studied within the IBD population. More recent data would suggest that bariatric surgery may be condom and feasible for IBD patients, peculiarly if performed in loftier-volume centers. The safety and effectiveness of varied weight loss interventions merit farther report for a population which is at present quite plagued with obesity, every bit aside from IBD outcomes, they would benefit from weight reduction for other health-related outcomes.
In conclusion, while there may certainly be an clan betwixt obesity and IBD in regards to disease pathogenesis, natural history, and response to therapy-"our understanding of this human relationship is limited. Further prospective studies utilizing measures of visceral adiposity as a proxy for obesity, as well as amend control of confounding factors, are required to amend our understanding and ultimately management of obesity in this already complex patient population.
Financial back up and sponsorship
Nil.
Conflicts of interest
In that location are no conflicts of interest.
| ane. | Seminerio JL, Koutroubakis IE, Ramos-Rivers C, Hashash JG, Dudekula A, Regueiro Thousand, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis 2015;21:2857-63.xs |
| 2. | Flores A, Burstein E, Cipher DJ, Feagins LA. Obesity in inflammatory bowel disease: A marker of less astringent affliction. Dig Dis Sci 2015;60:2436-45. |
| iii. | Pringle PL, Stewart KO, Peloquin JM, Sturgeon HC, Nguyen D, Sauk J, et al. Trunk mass alphabetize, genetic susceptibility, and gamble of complications amidst individuals with Crohn's illness. Inflamm Bowel Dis 2015;21:2304-10. |
| 4. | Nic Suibhne T, Raftery TC, McMahon O, Walsh C, O'Morain C, O'Sullivan M. Loftier prevalence of overweight and obesity in adults with Crohn'south disease: Associations with illness and lifestyle factors. J Crohns Colitis 2013;7:e241-8. |
| 5. | Lynn AM, Harmsen WS, Tremaine WJ, Loftus EV. Trends in the prevalence of overweight and obesity at the time of inflammatory bowel disease diagnosis: A population-based written report. Gastroenterology 2018;154 (6 Suppl):S614-5. |
| half-dozen. | Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: Non a passive bystander. Autoimmunity Rev 2014;13:981-1000. |
| 7. | Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-fifteen. |
| eight. | Fink C, Iordanes K, Bakirtzi K, Pothoulakis C. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis 2012;18:1550-7. |
| 9. | Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki Thou, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease Inflamm Bowel Dis 2006;12:100-5. |
| 10. | Ng SC, Shi HY, Hamidi N, Underwood Fe, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2017;390:2769–78. |
| 11. | Ho SM, Lewis JD, Mayer EA, Plevy SE, Chuang E, Rappaport SM, et al. Challenges in IBD inquiry: Environmental triggers. Inflamm Bowel Dis 2019;25(Suppl 2):S13-23. |
| 12. | Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 2013;145:970–7. |
| 13. | Ng Yard, Fleming T, Robinson Thou, Thomson B, Graetz Due north, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic assay for the Global Brunt of Disease Study 2013. Lancet 2014;384:766-81. |
| xiv. | Jensen CB, Ängquist LH, Mendall MA, Sørensen TIA, Baker JL, Jess T. Babyhood trunk mass alphabetize and adventure of inflammatory bowel disease in adulthood: A population-based accomplice study. Am J Gastroenterol 2018;113:694-701. |
| 15. | Chan SS, Luben R, Olsen A, Tjonneland A, Kaaks R, Teucher B, et al. Body mass index and the take chances for Crohn's disease and ulcerative colitis: Data from a European Prospective Cohort Study (The IBD in Ballsy Report). Am J Gastroenterol 2013;108:575-82. |
| 16. | Iannone F, Lopalco G, Rigante D, Orlando I, Cantarini L, Lapadula G. Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmun Rev 2016;15:447-50. |
| 17. | Lynn AM, Harmsen WS, Tremaine WJ, Bazerbachi F. Bear upon of obesity on hereafter IBD-related complications in a population-based accomplice of Crohn's affliction (CD) and ulcerative colitis (UC) patients. Gastroenterology 2018;154 (6 Suppl):S620-1. |
| 18. | Sharma S, Eckert D, Hyams JS, Mensing S, Thakkar RB, Robinson AM, et al. Pharmacokinetics and exposure-efficacy human relationship of adalimumab in pediatric patients with moderate to severe Crohn's affliction: Results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis 2015;21:783-92. |
| 19. | Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav Fifty, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: A population pharmacokinetic study. Inflamm Bowel Dis 2014;xx:2247-59. |
| 20. | Keizer RJ, Huitema Advert, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2012;49:493-507. |
| 21. | Harper JW, Sinanan MN, Zisman TL. Increased body mass alphabetize is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2118-24. |
| 22. | Mostafa NM, Nader AM, Noertersheuser P, Awni WM. Impact of immunogenicity on pharmacokinetics, efficacy and rubber of adalimumab in adult patients with moderate to severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2016;31:490-7. |
| 23. | Wade JR, Parker G, Kosutic Thou, Feagen BG, Sandborn WJ, Laveille C, et al. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn'south disease. J Clin Pharmacol 2015;55:868-74. |
| 24. | Passot C, Mullerman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, et al. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. MAbs 2016;8:1407-xvi. |
| 25. | Aubourg A, Picon L, Lecomte T, Bejan-Angoulvant T, Paintaud G, Ternant D. A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease. Eur J Clin Pharmacol 2015;71:1541-2. |
| 26. | Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49:71-87. |
| 27. | Bhalme M, Sharma A, Keld R, Willert R, Campbell South. Does weight-adjusted anti-tumour necrosis gene treatment favour obese patients with Crohn'south disease? Eur J Gastroenterol Hepatol 2013;25:543-9. |
| 28. | Dai ZH, Xu XT, Ran ZH. Associations betwixt obesity and the effectiveness of anti-tumor necrosis factor-α agents in inflammatory bowel disease patients: A literature review and meta-analysis. Ann Pharmacother 2020;54:729-41. |
| 29. | Kurnool S, Nguyen NH, Proudfoot J, Dulai PS, Boland BS, Vande Casteele N, et al. Loftier body mass index is associated with increased chance of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther 2018;47:1472-9. |
| 30. | Singh Southward, Proudfoot J, Xu R, Sandborn WJ. Obesity and response to infliximab in patients with inflammatory bowel diseases: Pooled assay of individual participant data from clinical trials. Am J Gastroenterol 2018;113;883-nine. |
| 31. | Singh Southward, Facciorusso A, Singh AG, Vande Casteele North, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select allowed-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One 2018;13:e0195123. |
| 32. | Wong ECL, Marshall JK, Reinisch W, Narula N. Body mass index does not touch clinical efficacy of ustekinumab in Crohn'south disease: A post hoc assay of the IM-UNITI trial. Inflamm Bowel Dis 2020:izaa214. doi: ten.1093/ibd/izaa214. |
| 33. | Gregory One thousand, Weaver KN, Hoversten P, Hicks SB, Patel D, Ciorba MA, et al. Efficacy of vedolizumab for refractory pouchitis of the Ileo-anal pouch: Results from a multicenter United states of america cohort. Inflamm Bowel Dis 2019;25:1569-76. |
| 34. | Moreau Air conditioning, Paul Southward, Del Tedesco E, Rinaudo-Gaujous M, Boukhadra North, Genin C, et al. Clan betwixt 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: A meta-analysis. Inflamm Bowel Dis 2014;20:464-71. |
| 35. | Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, et al. Significant differneces between Crohn's affliction and ulcerative coltis regarding the impact of body mass alphabetize and initial disease activity on responsiveness to azathioprine: Results from a European multicenter study in one,176 patients. Dig Dis Sci 2010;55:1066-78. |
| 36. | Poon SS, Asher R, Jackson R, Kneebone A, Collins P, Probert C, et al. Trunk mass index and smoking impact thioguanine nucleotide levels in inflammatory bowel disease. J Crohns Colitis 2015;9:640–vi. |
| 37. | Curtis JR, Westfall AO, Allison J. Population-based assessment of agin events associated with long-term glucocorticoid utilize. Arthritis Rheum 2006;55:420-6. |
| 38. | Berthon BS, MacDonald-Wicks LK, Wood LG. A systematic review of the effect of oral glucocorticoids on free energy intake, appetite, and body weight in humans. Nutr Res 2014;34:179-xc. |
| 39. | Wahl TS, Patel FC, Goss LE, Chu DI, Grams J, Morris MS. The obese colorectal surgery patient: Surgical site infection and outcomes. Dis Colon Rectum 2018;61:938-45. |
| 40. | McKenna NP, Mathis KL, Khasawneh MA, Dozois EJ, Larson DW, Pemberton JH, et al. Obese patients undergoing ileal pouch-anal anastomosis: Short-and long-term surgical outcomes. Inflamm Bowel Dis 2017;23:2142-half dozen. |
| 41. | Nastro P, Knowles CH, McGrath A, Heyman B, Porrett TR, Lunniss PJ. Complications of abdominal stomas. Br J Surg 2010;97:1885-9. |
| 42. | Efron JE, Uriburu JP, Wexner SD. Restorative proctocolectomy with ileal pouch anal anastomosis in obese patients. Obes Surg 2001;eleven:246-51. |
| 43. | Upala South, Sanguankeo A. Result of lifestyle weight loss intervention on affliction severity in patients with psoriasis: A systematic review and meta-assay. Int J Obes 2015;39:1197-202. |
| 44. | Al-Mutariri N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial. Proficient Opin Biol Ther 2014;fourteen:749-56. |
| 45. | Saxena A, Fletcher Due east, Larsen B, Baliga MS, Durstine JL, Fayad R. Upshot of exercise on chemically-induced colitis in adiponectin deficient mice. J Inflamm (Lond) 2012;9:30. |
| 46. | Chan D, Robbins H, Rogers South, Clark S, Poullis A. Inflammatory bowel disease and practise: Results of a Crohn's and Colitis UK survey. Frontline Gastroenterol 2014;5:44-8. |
| 47. | Loudon CP, Corroll V, Butcher J, Rawsthorne P, Bernstein CN. The furnishings of physical practise on patients with Crohn's disease. Am J Gastroenterol 1999;94:697-703. |
| 48. | Jones PD, Kappelman Physician, Martin CF, Chen Westward, Sandler RS, Long Doctor. Practice decreases risk of future agile disease in patients with inflammatory bowel disease in remission. Inflamm Bowel Dis 2015;21:1063-71. |
| 49. | Schauer PR, Bhatt DL, Kirwan JP, Wolski G, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes--three-year outcomes. N Engl J Med 2014;370:2002-13. |
| l. | Bazerbachi F, Sawas T, Vargas EJ, Haffar S, Deepak P, Kisiel JB, et al. Bariatric surgery is acceptably rubber in obese inflammatory bowel disease patients: Analysis of the nationwide inpatient sample. Obes Surg 2018;28:1007-fourteen. |
| 51. | Aminian A, Andalib A, Ver MR, Corcelles R, Schauer PR, Brethauer SA. Outcomes of bariatric surgery in patients with inflammatory bowel disease. Obes Surg 2016;26:1186-90. |
| 52. | Braga Neto MB, Gregory MH, Ramos GP, Bazerbachi F, Bruining DH, Abu Dayyeh BK, et al. Affect of bariatric surgery on the long-term illness course of inflammatory bowel affliction. Inflamm Bowel Dis 2020;26:1089-97. |
| 53. | Braga Neto MB, Gregory K, Ramos GP, Loftus EV Jr, Ciorba MA, Bruining DH, et al. De-novo inflammatory bowel disease after bariatric surgery: A big instance series. J Crohns Colitis 2018;12:452-7. |
| 54. | Cañete F, Mañosa M, Clos A, Cabré Due east, Domènech East. Review article: The relationship between obesity, bariatric surgery, and inflammatory bowel illness. Aliment Pharmacol Ther 2018;48:807-16. |
| 55. | Holt DQ, Moore GT, Strauss BJG, Hamilton AL, De Cruz P, Kamm MA. Visceral adiposity predicts post-operative Crohn's affliction recurrence. Aliment Pharmacol Ther 2017;45:1255-64. |
| 56. | Connelly TM, Juza RM, Sangster Due west, Sehgal R, Tappouni RF, Messaris E. Volumetric fat ratio and not torso mass alphabetize is predictive of ileocolectomy outcomes in Crohn'due south illness patients. Dig Surg 2014;31:219-24. |
Correspondence Address:
Dr. Amanda Thousand Johnson
Division of Gastroenterology and Hepatology, Mayo Dispensary, 200 First Street Southwest, Rochester, MN - 55905
USA
Source of Support: None, Conflict of Interest: None
DOI: 10.4103/sjg.sjg_30_21
| This article has been cited past | ||
| one | Tools for managing IBD in obese patients: Get JAK in the box! | |
| HananM Alrammah, Hanin AlMubayedh, Turki AlAmeel | ||
| Saudi Journal of Gastroenterology. 2021; 0(0): 0 | ||
| [Pubmed] | [DOI] | ||
Source: https://www.saudijgastro.com/article.asp?issn=1319-3767%3Byear%3D2021%3Bvolume%3D27%3Bissue%3D4%3Bspage%3D183%3Bepage%3D190%3Baulast%3DJohnson
Post a Comment for "De Novo Inflammatory Bowel Disease After Bariatric Surgery a Case Series and Literature Review"